10
Jun
2021

Biogen’s Alzheimer’s Controversy, Cytokine Startups Reload, and Vaccines Beat Variants

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

A Path Forward for More Biotech Workers
An Old Idea Whose Time Has Come
A Big Opportunity in Obesity
Regeneron Buys Checkmate, Bivalent Vaccine Progress, & a Fitting Acronym